Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

2-Year Follow-Up of the Randomized TWENTE Trial
Objectives
The aim of this study was to assess the safety and efficacy of the implantation of Resolute zotarolimus-eluting stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.
Background
Only limited long-term follow-up data are available from head-to-head comparisons of second-generation drug-eluting stents.
Methods
The randomized TWENTE (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente) trial is an investigator-initiated study performed in a population with many complex patients and lesions and only limited exclusion criteria. Patients were randomly assigned 1:1 to ZES (n ¼ 697) or EES (n ¼ 694).
Results
Two-year follow-up information was available on all patients. The rate of continuation of DAPT beyond 12 months was very low (5.4%). The primary endpoint of target vessel failure, a composite of cardiac death, target vesselrelated myocardial infarction, and target vessel revascularization, did not differ between ZES and EES (10.8% vs. 11.6, p ¼ 0.65), despite fewer target lesion revascularizations in patients with EES (2.6% vs. 4.9%, p ¼ 0.03). The patient-oriented composite endpoint was similar (16.4% vs. 17.1%, p ¼ 0.75). Two-year rates of definite or probable stent thrombosis were 1.2% and 1.4%, respectively (p ¼ 0.63). Very late definite or probable stent thrombosis occurred only in 2 patients in each study arm (0.3% vs. 0.3%, p ¼ 1.00).
Conclusions
After 2 years of follow-up and stringent discontinuation of DAPT beyond 12 months, Resolute ZES and Xience V EES showed similar results in terms of safety and efficacy for treating patients with a majority of complex lesions and off-label indications for drug-eluting stents. Second-generation drug-eluting stents (DES) such as the Xience V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) and the Resolute zotarolimuseluting stent (ZES) (Medtronic Inc., Santa Rosa, California) were developed to improve clinical outcome by overcoming the limitations of first-generation DES (1, 2) . The TWENTE (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente) trial is an investigator-initiated randomized study designed to compare the safety and efficacy of Resolute ZES with that of Xience V EES in a large patient population with complex coronary artery disease (3) . This patient population reflects routine clinical practice, as has recently been demonstrated by the findings of a study of eligible nonenrolled patients (4). In the TWENTE trial, the rates of the primary endpoint of target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically indicated target vessel revascularization (TVR), at 1 year were favorable and similar for Resolute ZES and Xience V EES. In addition, both stents did not significantly differ in the rates of several other secondary endpoints, such as stent thrombosis and a patient-oriented composite endpoint.
Only a few long-term data have been reported from randomized trials that compared second-generation DES in routine clinical practice. Although long-term data are available for the Xience V EES from several comparative studies of DES (5) (6) (7) (8) , only a single randomized study reported long-term outcome with the Resolute ZES (9). In addition, there is even less knowledge of the clinical performance of these DES after discontinuation of stringent dual antiplatelet therapy (DAPT) at 12 months. Use of DAPT was continued beyond 1 year in 13% to 69% of patients in previous comparative trials of DES (5, 8, 10) . In the TWENTE trial, however, a strict policy of discontinuation of DAPT after 12 months was followed, which is of interest for the present pre-specified 2-year analysis of clinical outcomes.
Methods
Study design and patient population. The TWENTE trial has previously been described in detail (3, 11) . In brief, the grants from Abbott Vascular and Medtronic. The research department of Thoraxcentrum Twente has received educational and/or research grants from Abbott Vascular, Biotronik, Boston Scientific, and Medtronic. Dr. von Birgelen is a consultant to and has received lecture fees or travel expenses from Abbott Vascular, Boston Scientific, and Medtronic; has received travel expenses from Biotronik; and has received a speaker's honorarium from Merck Sharpe & Dohme. All other authors have reported that they have no relationships relevant to the content of this paper to disclose.
Manuscript Intervention, medication, and in-hospital course. Patients were pre-treated with acetylsalicylic acid and clopidogrel. At discharge, the combination of acetylsalicylic acid 100 mg once daily indefinitely and clopidogrel 75 mg once daily for 12 months was prescribed. Use of DAPT was determined by patient questionnaire and/or information from each patient's general practitioner or pharmacy. Lesion pre-dilation, direct stenting, stent post-dilation, and/or use of glycoprotein IIb/IIIa antagonists were permitted at the operators' discretion. Liberal use of post-dilation was encouraged. Cardiac biomarkers and electrocardiograms were systematically assessed in all patients before and after PCI to identify periprocedural MI. Definitions of clinical endpoints. Definitions of all clinical endpoints have previously been described in detail (3). The primary clinical endpoint was the incidence of TVF at 1 year, a composite endpoint that was defined as cardiac death, target vessel-related MI (or not attributable to a nontarget vessel), and clinically driven TVR. The pre-specified secondary endpoints included TVF at 2-year follow-up, all-cause mortality, stent thrombosis, target lesion failure (TLF), major adverse cardiac events, and a patient-oriented composite endpoint consisting of all-cause mortality, any MI, and any repeat revascularization. All clinical endpoints, including stent 
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The TWENTE 2-Year Outcome After 12 Months of DAPT June 18, 2013 June 18, :2406 thrombosis, were defined according to the Academic Research Consortium, including the addendum to the/? definition of MI (12, 13) . Acquisition and analysis of clinical data. Clinical follow-up data were obtained at visits to outpatient clinics or, if not feasible, by telephone follow-up and/or medical questionnaire. Follow-up data were available in all but 4 patients, who withdrew informed consent during the course of the study (2 patients in the Resolute ZES group and 2 patients in the Xience V EES group). Processing of clinical data and adjudication of all adverse clinical events were performed by an independent external contract research organization (Cardialysis, Rotterdam, the Netherlands). Analyses were performed on the basis of the principle of intention-to-treat. Statistical analysis. Statistical analyses were performed with SPSS version 15.0 (SPSS Inc., Chicago, Illinois). Categorical variables were assessed with the chi-square test or Fisher exact test as appropriate, whereas continuous variables were assessed with the Wilcoxon rank sum test or Student t test as appropriate. The times to the primary endpoint and to the components thereof were assessed according to the Kaplan-Meier method, and the log-rank test was applied to compare the 2 groups. A landmark analysis was performed at 1 year for various events. For each type of event, patients were excluded from the landmark analysis if the specific event or death occurred in the first year. Unless otherwise specified, p values and confidence intervals were 2 sided. A p value <0.05 was considered significant.
Results
A total of 1,391 patients were randomized to treatment with Resolute ZES (n ¼ 697) or Xience V EES (n ¼ 694). Apart from 4 patients who withdrew their consent during the first year of follow-up, 2-year follow-up information was obtained from all patients (Fig. 1) . Baseline clinical, Values are n (%) or mean AE SD. *Chronic renal failure was defined as a serum creatinine level !130 mmol/l. yOff-label stent use included renal insufficiency, an ejection fraction <30%, the occurrence of acute myocardial infarction within the previous 72 h, more than one lesion per vessel, at least 2 vessels with stents, a lesion measuring more than 27 mm, bifurcation, bypass grafts, in-stent restenosis, unprotected left main artery, lesions with thrombus, or total occlusion. zThrombus triggering use of thrombus aspiration catheters. ACC ¼ American College of Cardiology; AHA ¼ American Heart Association.
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The TWENTE 2-Year Outcome After 12 Months of DAPT angiographic, and procedural characteristics of all study patients are summarized in Table 1 . At 2-year follow-up, the composite primary endpoint of TVF occurred in 75 patients (10.8%) in the Resolute ZES group and in 80 patients (11.6%) in the Xience V EES group and did not differ significantly between groups (absolute difference: À0.8 [À4.1 to 2.6]; p ¼ 0.65) ( Table 2, Fig. 2 ). The patient-oriented composite endpoint rates were also similar for patients treated with ZES and EES; this endpoint occurred in 114 patients (16.4%) versus 118 patients (17.1%), respectively. For the individual components of the composite primary endpoint of TVFdcardiac death (1.6% vs. 2.7%, p ¼ 0.14), target vessel-related MI (5.3% vs. 5.6%, p ¼ 0.80), and clinically driven TVR (5.6% vs. 5.1%, p ¼ 0.65)d there was also no significant difference at 2 years. The results of an exploratory subgroup analysis at 2-year follow-up with regard to TVF are shown in Figure 3 . The subgroup analysis showed consistent results across different subgroups. Compared with Resolute ZES, the use of Xience V EES was associated with a lower rate of clinically indicated target lesion revascularization (TLR) (4.9% vs. 2.6%, p ¼ 0.03), but this did not result in a significant difference in the device-oriented composite endpoint of TLF (10.5% vs. 9.8%, p ¼ 0.68). Table 3 shows the difference in outcome between 1-year and 2-year follow-up. No significant difference was observed for various endpoints. However, there were numerically more cardiac deaths among patients in the Xience V EES group (0.6% vs. 1.3%, p ¼ 0.16) and numerically more clinically indicated cases of TLR in the Resolute ZES group (2.3% vs. 1.2%, p ¼ 0.13).
In accordance with national and European guidelines, the per-protocol duration of DAPT was 1 year after PCI. Table 4 presents data on the actual use of DAPT. DAPT was discontinued after 1 year or less in 635 patients (93.4%) in the Resolute ZES group and 650 patients (95.9%) in the Xience V EES group. Of all patients, 73 (5.4%) continued DAPT beyond 12 months. At 2-year follow-up, 51 patients (7.7%) in the Resolute ZES group and 40 patients (6.2%) in the Xience V EES group were still on DAPT.
The rates of ARC-defined definite stent thrombosis (0.9% vs. 0.1%, p ¼ 0.12) and definite or probable stent thrombosis (1.2% vs. 1.4%, p ¼ 0.63) at 2-year follow-up were low and similar for both Resolute ZES and Xience V EES (Fig. 4) . Very late definite or probable stent thrombosis was seen in 2 patients in both study arms (0.3% vs. 0.3%, p ¼ 1.00), resulting in an MI in all 4 cases (Table 5) . Of the 14 patients with definite or probable stent thrombosis in the first year of follow-up, 11 (78.6%) were on DAPT. All 4 patients with very late definite or probable stent thrombosis were on acetylsalicylic acid monotherapy Values are n (%). *Major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, and clinically indicated target lesion revascularization. yPatient-oriented composite endpoint is a composite endpoint of all-cause death, any myocardial infarction, and any revascularization.
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The TWENTE 2-Year Outcome After 12 Months of DAPT June 18, 2013:2406-16 beyond 1 year and there was no clear relation between stent thrombosis and discontinuation of DAPT, with a period of at least 79 days between very late stent thrombosis and discontinuation of DAPT.
Discussion
At the 2-year follow-up of the TWENTE trial, which followed a stringent approach of discontinuation of DAPT after 12 months, Resolute ZES and Xience V EES showed similar and beneficial results in terms of safety and efficacy for treating real-world patients who underwent PCI with a vast majority of complex lesions and off-label indications for use of DES. Both study arms showed similar rates of TVF and its components: cardiac death, target vessel-related MI, and clinically indicated TVR. The absence of a difference in TVF at 2-year follow-up was consistent across several subgroups. Despite a lower rate of clinically indicated TLR in the Xience V EES group, there was no significant difference between groups in the device-oriented composite endpoint of TLF and the more patient-oriented composite clinical endpoints (major adverse cardiac events and patientoriented composite endpoint). Resolute ZES and Xience V EES are both secondgeneration DES that use cobalt-chromium stent platforms and elute limus analogues from durable polymer-based coatings with improved biocompatibility (14, 15) . This improvement in coating was considered desirable because the limited biocompatibility of coatings on first-generation DES (16-18) was found to be associated with hypersensitivity and local vascular inflammation that could induce intraluminal thrombus formation (19) (20) (21) .
In several randomized comparisons with first-generation DES, Xience V EES have demonstrated proven sustained safety and efficacy beyond 1 year, which has led to wide acceptance in clinical practice. In SPIRIT IV (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System IV), treatment with Xience V EES was Values are % (n/N) *Major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, and clinically indicated target lesion revascularization. yPatient-oriented composite endpoint is a composite endpoint of all-cause death, any myocardial infarction, and any revascularization.
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The TWENTE 2-Year Outcome After 12 Months of DAPT June 18, 2013 June 18, :2406 SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) demonstrated that Xience V EES had similar and low rates of TLF at 2-year follow-up but showed noninferiority compared with the first-generation sirolimus-eluting stent Cyper Selectþ (Cordis, Bridgewater, New Jersey) (6).
Only a single randomized study, the RESOLUTE All Comers trial, has reported long-term outcome data for Resolute ZES. After 2 years, Resolute ZES were equivalent to Xience V EES with regard to both TVF (12.6% vs. 12.2%, p ¼ 0.85) and the patient-oriented composite endpoint (20.6% vs. 20.5%, p ¼ 0.96) (9) .
The current 2-year data of the TWENTE trial generally support the findings of the RESOLUTE All Comers trial and show that Resolute ZES have a long-term safety profile that is similar to that of Xience V EES, which was previously shown to be superior to the Taxus stent in SPIRIT IV and COMPARE (5, 8) . Although the rates of TLR for Resolute ZES and Xience V EES were similar in the RESOLUTE All Comers trial (5.7% and 5.1%, respectively), in the TWENTE trial the rate of TLR for Xience V EES was particularly low, resulting in a statistically significant difference (4.9% vs. 2.6%, p ¼ 0.03). However, this difference did not translate into a difference in the device-oriented composite endpoint of TLF because of a numerically higher cardiac death rate in the Xience V EES group (1.4% vs. 2.6%, p ¼ 0.14). In fact, the Kaplan-Meier cumulative event curves of cardiac death tend to diverge after approximately 10 months, but a landmark analysis revealed only a nonsignificant difference in cardiac death during the second year of follow-up (0.6% vs.1.3%, p ¼ 0.16). Nevertheless, these data suggest that assessment of this parameter beyond the present 2-year follow-up may be of interest.
At 2-year follow-up in the TWENTE trial, the rates of 2-year definite or probable stent thrombosis (1.2% vs. 1.4%) and very late definite or probable stent thrombosis (0.3% for both arms) were low for both Resolute ZES and Xience V Table 4 Use of Acetylsalicylic Acid, Clopidogrel, and Dual Antiplatelet Therapy Tandjung et al.
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The TWENTE 2-Year Outcome After 12 Months of DAPT EES. These data are reassuring for Resolute ZES, considering that optical coherence tomography data had shown more uncovered stent struts with Resolute ZES than with Endeavor stents (22) . The rates of stent thrombosis were similar to those in the RESOLUTE All Comers trial (2-year rate of definite or probable stent thrombosis, 1.9% vs. 1.0%; 2-year rate of very late definite or probable stent thrombosis, 0.3% vs. 0.3%) as well as the rates of stent thrombosis for Xience V EES in SORT OUT IV and COMPARE (5,6,9). In addition, the 2-year rates of definite or probable stent thrombosis in the TWENTE trial were similar to the pooled 2-year rates of stent thrombosis in SPIRIT II and III (1.2%), using Xience V EES in selected patient populations with/? more stable coronary disease (23).
The 2-year rates of definite stent thrombosis in the TWENTE trial were also low, showing a nonsignificant trend toward a lower rate in the Xience V EES group (p ¼ 0.12). Nevertheless, it may be difficult to directly compare rates of stent thrombosis from different trials, because they could be influenced by differences in study populations. In the TWENTE trial, just one of the overall 7 definite stent thromboses was lethal, while very late The TWENTE 2-Year Outcome After 12 Months of DAPT June 18, 2013 June 18, :2406 definite or probable stent thrombosis was not associated with mortality. Similar findings were observed in other studies evaluating second-generation DES (5, 6, 9) . The overall low rates of stent thrombosis and low rates of mortality associated with stent thrombosis in patients in the Resolute ZES group were similar to those in patients in the Xience V EES group, which has shown the lowest rates of stent thrombosis in comparison to earlier-generation DES (24, 25) . The data of the TWENTE trial underline the safety profile of both second-generation DES.
The low rates of very late stent thrombosis in the TWENTE trial are particularly noteworthy considering the low rate of continuation of DAPT beyond 12 months, which was in accordance with current guidelines (26, 27) . In fact, the rate of DAPT use at 2-year follow-up (6.9%) was much lower than that of several European DES trials in allcomer populations, such as LEADERS (23%) (10, 28) , RESOLUTE All Comers (18%) (9) , and COMPARE (13%) (5), and some U.S. trials of DES in patients with somewhat less complex coronary disease, such as SPIRIT IV (69%) (8, 29) and RESOLUTE US (67%) (30, 31) . In addition, in the second year of follow-up after discontinuation of DAPT, rate of definite or probable stent thrombosis was lower compared with that with first-generation DES, which showed a definite and continuous risk of very late stent thrombosis (32) . Hence, the TWENTE trial provides interesting safety information on stringent discontinuation of DAPT at 1 year after PCI in a study population with many complex patients and lesions treated with Resolute ZES and Xience V EES. Study limitations. This prospective, randomized, singlecenter trial was performed in a high-volume tertiary care center by experienced operators who applied relatively uniform procedural strategies. For that reason, generalizability of the study results to other clinical settings may be limited. In addition, conclusions do not apply to patients with STsegment elevation MI requiring primary PCI, because this patient subset was not assessed in the TWENTE trial. The subgroup analysis was not pre-specified. However, to avoid any subjective post hoc selection, we used the same subgroups as the RESOLUTE All Comers trial (33) and the 1-year analysis of the TWENTE trial (3).
Conclusions
After 2 years of follow-up and stringent discontinuation of DAPT beyond 1 year, Resolute ZES and Xience V EES showed similar results in terms of safety and efficacy for treating real-world patients with a majority of complex lesions and off-label indications for DES.
